Blocking HO-1 Enzyme Breaks Cisplatin Resistance in Lung Cancer
Two small molecules—SB 202190 and NDGA—restore cancer cell death by targeting the HO-1 enzyme that shields tumors from chemotherapy.
Summary
Cisplatin resistance is the leading obstacle in non-small cell lung cancer (NSCLC) chemotherapy. Researchers identified HMOX1 (encoding HO-1) as a master resistance gene by sequencing cisplatin-resistant NSCLC cell lines and validating findings in GEO and TCGA databases. The Nrf2/HO-1 pathway was shown to suppress ferroptosis—an iron-dependent cell death mechanism that cisplatin normally triggers. Two small-molecule compounds, SB 202190 and NDGA, were discovered through molecular docking to directly bind and inhibit HO-1, restoring ferroptosis sensitivity and dramatically improving cisplatin efficacy in both lab and mouse tumor models. This work positions HO-1 as a credible, druggable target for overcoming platinum resistance in lung cancer.
Detailed Summary
Lung cancer kills more people globally than any other cancer, and NSCLC accounts for 85% of cases. Cisplatin-based regimens remain first-line treatment, but resistance develops frequently and the molecular mechanisms remain incompletely understood. This study set out to identify actionable resistance genes and compounds to counteract them.
The research team constructed cisplatin-resistant NSCLC cell lines (A549-R, H23-R, H460-R) by stepwise drug escalation, then performed transcriptome sequencing and compared results against GEO drug-resistance datasets and TCGA clinical data. HMOX1—encoding Heme Oxygenase 1 (HO-1), a downstream target of the master antioxidant regulator Nrf2—emerged consistently as the most significantly upregulated gene in resistant cells and correlated with poorer clinical outcomes in NSCLC patients.
Mechanistic experiments showed that elevated Nrf2/HO-1 signaling neutralizes reactive oxygen species and blocks ferroptosis, the iron-dependent oxidative cell death that cisplatin partly relies on to kill tumor cells. Knockdown of HMOX1 via siRNA re-sensitized resistant cells to cisplatin and restored ferroptosis markers. Conversely, overexpressing HMOX1 in sensitive A549 cells recapitulated resistance. Co-treatment with ferroptosis inhibitors (Ferrostatin-1) or iron chelators (Deferoxamine) confirmed that ferroptosis suppression is a central mechanism of HO-1-driven resistance.
To find druggable solutions, the team conducted virtual screening of over 10,300 bioactive compounds against the HO-1 crystal structure (PDB: 6EHA) using Schrödinger Maestro. SB 202190 (a p38 MAPK inhibitor with newly identified HO-1 binding) and Nordihydroguaiaretic acid (NDGA, a plant-derived lipoxygenase inhibitor) emerged as top candidates. Proteomics and molecular docking confirmed direct HO-1 binding. In A549-R cells, both compounds synergized with cisplatin (combination index <1 by Chou-Talalay method), suppressed Nrf2/HO-1/GPX4 pathway proteins, and reactivated ferroptosis. In mouse xenograft models, cisplatin plus SB 202190 or NDGA significantly reduced tumor growth compared to cisplatin alone, without notable organ toxicity on liver, kidney, or cardiac biomarkers.
The study provides the first integrated evidence—spanning cell biology, bioinformatics, structural biology, and in vivo pharmacology—that HO-1 is a bona fide therapeutic target for platinum resistance in NSCLC. It also reframes ferroptosis suppression as a core, HO-1-dependent resistance mechanism rather than a secondary effect, opening the door to combination strategies using HO-1 inhibitors clinically.
Key Findings
- HMOX1 is the top upregulated gene in cisplatin-resistant NSCLC cells, confirmed across transcriptomics, GEO, and TCGA datasets.
- Nrf2/HO-1 pathway activation suppresses ferroptosis, enabling tumor cells to survive cisplatin-induced oxidative stress.
- siRNA knockdown of HMOX1 restores cisplatin sensitivity; HMOX1 overexpression transfers resistance to sensitive cells.
- SB 202190 and NDGA bind HO-1 directly and synergize with cisplatin to shrink resistant tumors in mouse xenografts.
- Combination therapy showed no significant liver, kidney, or cardiac toxicity in animal safety assessments.
Methodology
Cisplatin-resistant NSCLC cell lines were built by stepwise drug escalation; transcriptome sequencing was cross-validated with GEO and TCGA databases. HO-1 inhibitor candidates were identified via virtual screening of 10,300+ compounds docked to HO-1 crystal structure (PDB: 6EHA), then tested in vitro (CCK-8, siRNA knockdown, western blotting, ferroptosis assays) and in vivo in nude mouse subcutaneous xenograft models.
Study Limitations
All in vivo work used immunocompromised nude mouse xenografts, limiting conclusions about immune interactions. The clinical relevance of the SB 202190 and NDGA dosing regimens used in mice requires pharmacokinetic and toxicology validation in humans. The study does not address whether pre-existing HMOX1 expression levels in patient biopsies can prospectively predict resistance onset.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.